Aqueous steroid formulations for nasal administration

Details Aqueous steroid formulations for nasal administration Aqueous steroid formulations for nasal administration

1988-09-20

1991-01-08

Friedman, Stanley J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

514886, A61K 3158

Patent

active

049835955

ABSTRACT:
A non-stinging aqueous anti-inflammatory steroid formulation suitable for intranasal administration comprises: an anti-inflammatory steroid in an amount between about 0.01% and about 0.05% (w/v); propylene glycol in an amount between about 2% and about 10% (w/v); PEG 400 in an amount between about 10% and about 25% (w/v); polysorbate 20 in an amount between about 1% and about 4% (w/v); an effective amount of a preservative; an effective amount of a stabilizer; an effective amount of an antioxidant; water; and pH buffering agent sufficient to adjust the pH of the resulting solution to between about 3.5 and about 7.

REFERENCES:
patent: 4444762 (1984-04-01), Rajadhayaksha
patent: 4782047 (1988-11-01), Benjamin et al.
Physicians Desk Reference, 38th Edition (1984), p. 1981; Nasalide.RTM..

Affiliated with

Also associated with

Rating

Aqueous steroid formulations for nasal administration does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aqueous steroid formulations for nasal administration, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aqueous steroid formulations for nasal administration will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-934941